Dear colleagues, partners, and friends,
As we conclude another remarkable year, we want to extend our sincere gratitude to each of you; our distributors, collaborators, and partners around the world.
2024–2025 has been a year defined by progress, dialogue, and renewed momentum in the MASLD/MASH field. We are truly grateful for the continued trust, engaged discussions, new scientific contacts, and the many constructive conversations we’ve shared with you throughout the year.
The global MASLD landscape is evolving faster than ever. The release of Rezdiffra™ in the United States has already brought meaningful benefit to many patients, marking a long-awaited step forward in treatment availability. With the recent approval in Europe, we are excited to see this progress finally reach European patients, which is a milestone the field has been anticipating for decades.
Likewise, the approval of semaglutide for MASH adds an important therapeutic option. After years of limited tools, we are now entering a new phase where patients with MASH can finally receive the help they need.
But as treatment availability expands, a new challenge has emerged:
How do we effectively monitor patients on therapy?
This question has been raised repeatedly in our conversations with clinicians, KOLs, and partners this year, and it is becoming one of the central needs in clinical practice.
In this evolving landscape, M30 Apoptosense® ELISA has shown clear potential to fill an important part of this gap.
Evidence from multiple clinical trials, including Madrigal’s phase III MAESTRO-NASH trial, has shown that M30® (ccK18) is one of the leading blood-based indicators of treatment response, outperforming several structural NITs in early prediction of change. Importantly, M30® offers:
- – Early, biology-based insight into hepatocellular injury
- – Reliable tracking of treatment effect before structural changes become visible
- – A practical solution for clinics without access to advanced imaging such as MRI-PDFF
- – A low-cost, accessible assay that integrates easily into routine follow-up workflows
As more patients in the US and Europe begin therapy, the need for simple, repeatable, blood-based monitoring tools has never been clearer. We are proud that our M30 Apoptosense® ELISA continues to serve as a scientifically grounded, widely studied option to support clinicians and improve real-world treatment follow-up.
Looking ahead to 2026, we are excited to continue supporting you; through scientific collaboration, distributor partnerships, educational materials, and tools that strengthen your local markets. Your work is essential for bringing knowledge, clarity, and better care to patients worldwide, and we value the role you play in this shared mission.
From all of us at VLVbio:
Thank you for a productive, inspiring, and forward-moving year.
We look forward to continuing our work in 2026.
The VLVbio Team
